Post hoc subgroup analysis of PULSAR in neovascular AMD (869 completed 96 weeks): aflibercept 8 mg every 12 or 16 weeks gave visual and anatomic outcomes comparable to 2 mg every 8 weeks across baseline disease severity subgroups.
Secondary analysisn = 869
Gale et al. PULSAR: Clinical Outcomes of Aflibercept 8 mg with Extended Dosing and 2 mg in Neovascular Age-Related Macular Degeneration in Subgroups Defined by Baseline Characteristics